EQS-News: SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory
“With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.
- “With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.
- We will continue to benefit from key pharma trends and the overall market growth for injectable drugs”, said Almuth Steinkühler, CFO of SCHOTT Pharma.
- In 2023, SCHOTT Pharma continued to deliver on its strategy and achieved several milestones along the pillars expansion and innovation.
- On the innovation side, SCHOTT Pharma successfully introduced two leading innovations to the market that serve the pharma megatrends Glucagon-like peptide-1 (GLP-1) and mRNA.